Compare Upstart Holdings Inc (UPST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upstart Holdings Inc vs Viatris Inc — how do they compare? Upstart Holdings Inc trades at $24.1 (market cap $2.35B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 8.5× Upstart Holdings Inc's market cap, and Viatris Inc pays a 2.75% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Upstart Holdings Inc for 39 Days and Viatris Inc for 57 Days on average.
| UPST | VTRS | |
|---|---|---|
Market Cap | $2.35B | $20.03B |
Volume | 4,203,337 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $52.74 | $18.27 |
52-Week Low | $22.81 | $9.74 |
Typical Hold Time | 39 Days | 57 Days |
Enterprise Value | $3.88B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UPST trades at $24.19, up 0.71% with bearish technical signals despite recent partnership expansions. The company shows improving fundamentals with revenue growing to $1.02B in 2025 and achieving profitability with $53.6M net income. However, recent earnings misses and negative operating cash flow of -$147.73M raise concerns. Analyst sentiment remains divided with a $39.50 price target suggesting 63% upside potential from current levels.
The stock presents a high-risk opportunity with significant upside potential if the company can sustain revenue growth and improve cash flow generation. Key risks include ongoing earnings volatility, credit market sensitivity, and high debt levels. The AI lending platform's expansion into HELOC and auto lending could drive future growth, but execution remains critical for investor confidence.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
